PCR was used to evaluate the occurrence of Toxoplasma gondii parasitemia by detection of the B1 gene in blood samples in two groups of immunosuppressed patients (148 subjects) suspected of having cerebral or extracerebral infection, respectively. Group I consisted of 52 patients with AIDS with suspected cerebral toxoplasmosis. The diagnosis was clinically proven in 15 cases. Parasitemia was detected by PCR in only two of these patients (13.3%), both showing evidence of disseminated infection. Group II consisted of 96 immunocompromised patients, either with AIDS or receiving iatrogenic immunosuppressive therapy. Of these patients, 65 (34 with AIDS and 31 others) showed abnormalities only in chest radiography and were first screened for the presence of Toxoplasma DNA in bronchoalveolar lavage fluid. Blood was then analyzed when the parasite was detected in the bronchoalveolar lavage fluid. The remaining 31 subjects (22 with AIDS and 9 others) were suspected of having extracerebral, pulmonary, or disseminated toxoplasmosis, and blood was studied directly in these cases. Among the nine patients with clinically diagnosed extracerebral infection in group II, the parasite was detected by PCR in the blood of five patients (55.5%), all having pulmonary toxoplasmosis. If all patients with clinical manifestations of extracerebral toxoplasmosis (from both groups) who had not received antitoxoplasma therapy when the samples were collected are considered, PCR detected parasitemia in seven of the nine cases (77
In recent years, Toxoplasma gondii has emerged as an important life-threatening opportunistic pathogen in immunocompromised patients. In the United States, toxoplasmic encephalitis has been estimated to occur in one-third of AIDS patients with latent T. gondii infection (29) . In Europe and Africa, where a higher prevalence of latent infection is present, 25 to 50% of patients with AIDS will ultimately develop toxoplasmic encephalitis (30, 33) . The lung was found to be one of the most common sites of extracerebral toxoplasmosis in immunocompromised patients (7, 39) . Involvement of the central nervous system and the lung may occur alone or in association with disseminated toxoplasmosis affecting multiple organs such as the heart, liver, kidney, lymph nodes, adrenal glands, bone marrow, stomach, colon, and testes (3, 31, 39) . While published data indicate that toxoplasmic encephalitis usually results from the local reactivation of latent infection (28, 29) , recent reports of the isolation of the parasite from blood of patients with toxoplasmic encephalitis (17, 18, 38) suggest the systemic nature of the disease in some cases. Pulmonary toxoplasmosis may result from the local rupture of latent cysts or be due to the spread of the parasite from distant sites (31) . Since most of these patients have immunoglobulin G (IgG) antitoxoplasma antibodies from latent infection and IgM antibodies are rarely found (27) , for diagnosis it is necessary to detect the parasite by direct methods. These approaches are time-consuming, requiring up to 6 weeks for mouse inoculation (16) and 4 to 10 days for less sensitive tissue culture (15) . Furthermore, in many cases they make invasive intervention such as brain biopsy or bronchoscopy necessary. This necessitates the consideration of new, noninvasive, rapid and sensitive techniques. One method that has been used successfully in this regard for the detection of T. gondii in clinical specimens is PCR (5, 17, 19-21, 24, 36) .
Here, we report on 11/2 years of experience in employing PCR to detect T. gondii DNA in samples obtained from immunocompromised AIDS patients and transplant recipients. The aim of our study was to explore further the value of PCR for detecting the parasite in blood samples in cases of suspected cerebral and extracerebral toxoplasmosis.
MATERIALS AND METHODS
Study groups. The study included a total of 186 patients composing two groups (groups I and II) with suspected cerebral and extracerebral toxoplasmosis, respectively, as shown in Table 1 increasing the urea concentration and the stringency wash temperature to a maximum of 50°C, the maximum tolerated by the peroxidase (optimal conditions used for the lower panels were 42% [wt/vol] urea and a temperature of 48°C). Lanes: 1, 12, and 16, positive-control DNA from 25, 1, or 5 T. gondii tachyzoites, respectively; 2 and 14, negative controls (no DNA added); 6 and 10, positive blood samples from patients 17 and 19 (see Table 3 ); 3 to 5, 7 to 9, 11, and 13 to 15, negative blood samples. then resuspended in 2.5 ml of PBS. Each sample was divided into two portions which were injected intraperitoneally into two 10-week-old NMRI mice. In the case of CSF or BAL fluid, 0.5-and 1-ml samples, respectively, were injected directly intraperitoneally into each of two mice. Mouse inoculation was considered positive if dissection of the mice revealed intraperitoneal tachyzoites or brain cysts or if the mice developed antitoxoplasma antibodies detected by the dye test (titer, .1,000 IU/ml).
Processing samples by PCR DNA was prepared and amplified as previously described by Roth et al. (36) . Briefly, DNA was released from the cell pellets obtained after lysis and centrifugation of 500 ,u1 of EDTA-treated blood as mentioned above or centrifugation of 1 ml of CSF or BAL fluid by means of proteinase K digestion. The supernatant of the resulting crude cell lysate was analyzed for the presence of the T gondii BJ gene, previously described by Burg et al. (5) . Three oligonucleotide primers were used: P3, 5'-ClTCAAGCAG CGTATTGTCG-3', corresponding to nucleotides 661 to 680 of the sense strand of the gene; P7, 5'-TAAAGCGTTCGTG GTCAACT-3', corresponding to nucleotides 864 to 833 of the antisense strand; and P8, 5'-GGAACTGCATCCGTICA TGA-3', corresponding to nucleotides 694 to 713 also of the sense strand of the gene. P3 and P7 initiate the amplification of a 223-bp fragment, whereas P8 and P7 generate a 190-bp fragment partially internal to the first fragment. The first fragment was used as the target for the amplification reaction, while the second purified fragment was used as the detecting probe. The amplification reaction was done in a 50-,ul reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 0.01% gelatin, 250 p.M (each) deoxynucleotide triphosphates (dATP, dGTP, dCTP, and dUTP), 12.5 pmol of each primer, 1 U of Thermus aquaticus DNA polymerase (all reagents were from Boehringer Mannheim GmbH, Mannheim, Germany), and 10 p.l of crude DNA. The reaction was from five tachyzoites. Strict measures to avoid contamination were employed (25) . To avoid the possibility of carryover contamination, dUTP was used instead of dTTP in the reaction mixture (26) . Positive samples were retested after being treated with uracil-DNA-glycosylase (GIBCO, Eggenstein, Germany). Samples which yielded positive results at least two times and after treatment with glycosylase were considered positive.
RESULTS
Specificity and sensitivity of PCR. The method of directly labeling long nucleic acid probes with peroxidase leads to the introduction of an average of one peroxidase complex every 25 bases. To ensure a high sensitivity, we tried to produce as long a probe as possible. As a result, the probe was not completely internal to the fragment amplified in clinical samples. However, experiments to optimize the stringency of the Southern hybridization method demonstrated that specificity was not impaired (Fig. 1) . To (9) and that the BJ gene is a 35-copy gene (5), detection of 0.01 fg of the 223-bp fragment is equivalent to the detection of approximately one parasite. Moreover, T. gondii DNA was detected by this PCR procedure in all blood samples from 10 mice 3 days after intraperitoneal inoculation with 1.6 X 106 BK strain tachyzoites (36) .
In all the samples tested, crossover contamination occurred on only two occasions. These samples were found to be negative after treatment with uracil-DNA-glycosylase.
Serology, mouse inoculation, and PCR for the study groups. The patients studied were divided in two groups on the basis of original clinical suspicion of cerebral or extracerebral toxoplasmosis before a definite diagnosis could be established. Altogether, acute toxoplasmosis was diagnosed in 24 (38) . In a recent study, 9 of 13 patients (69.2%) with clinically confirmed cerebral toxoplasmosis had T. gondii DNA in their blood when samples were examined by PCR (17) . In both studies, the samples were tested before the patients received any antitoxoplasma treatment. In our study, 3 of the abovementioned 15 patients were under treatment for 4 weeks before samples were collected. Considering only patients who had not received any therapy or who had been treated for less than 1 week when their blood samples were collected, we find that PCR detected parasitemia in 2 of 10 patients with cerebral toxoplasmosis (20%).
In the last few years, many reports concerning the occurrence of extracerebral toxoplasmosis, especially pulmonary toxoplasmosis, in AIDS patients and organ transplant recipients have been published (2, 3, 6, 7, 10, 12-14, 22, 31, 34, 36) . In a recent study of 80 AIDS patients at autopsy, extracerebral involvement was revealed in 13 cases (16.2%) (23) .
Analysis of the results for patients from group II with extracerebral manifestation of toxoplasmosis shows that T gondii DNA was detected by PCR in 6 of the 77 BAL samples examined (7.7%). Of the seven patients with pulmonary toxoplasmosis, parasite DNA was detected by PCR in the blood of five. This finding indicates that the disease was disseminated VOL. 32, 1994 on July 6, 2017 by guest http://jcm.asm.org/ Downloaded from but also demonstrates the value of the examination of blood by PCR in cases of pulmonary toxoplasmosis. This dissemination coincides with the nature of pulmonary toxoplasmosis, which usually results from invasion of the lung by parasites coming from reactivated, distant infection (31) and is usually accompanied by the infection of other organs, as indicated by autopsy studies (23) . Of the nine patients with extracerebral toxoplasmosis in group II, parasitemia was detected by PCR in only five (55.5%). This percentage is affected by the absence of parasites in the blood of the last two patients, who had already undergone 4 weeks of antitoxoplasma therapy before the samples were taken. The absence of the parasite in the blood of three of the four non-AIDS patients with extracerebral toxoplasmosis in group II might reflect the better immunological status of these patients, since they all developed IgM antibodies. This immunological response might have contributed to the rapid clearance of the parasites from the blood. Indeed, considering only the AIDS patients with extracerebral infection in both groups (two from group I and five from group II), we find that PCR detected parasitemia in six (all as yet untreated when the samples were obtained), equivalent to 85.7%. In summary, if we consider all nine patients in both groups, either with or without AIDS, with extracerebral manifestation of toxoplasmosis who had not received antitoxoplasma therapy when the samples were collected (two from group I and seven from group II), PCR detected parasitemia in seven (77.8%; negative predictive value 0.98; 141 patients studied).
The results obtained in this study show that if PCR is applied to help establish diagnosis of toxoplasmosis using blood samples, it is important to consider whether cerebral or disseminated manifestation is occurring. We have shown that the sensitivity of the assay increases significantly in cases where a dissemination of the parasites can be expected. Examination of autopsy samples from patients with AIDS in the United States (39) and Germany (23) showed that 14.3 and 29%, respectively, of cases with cerebral toxoplasmosis were associated with extracerebral involvement. This coincides with our finding that analysis of blood in cerebral toxoplasmosis by PCR yielded a low negative predictive value. Therefore, only selected samples should be tested in a clinical situation in order to increase the validity of this diagnostic tool. The PCR method used in the present study detects DNA obtained from cell pellets of the sample; thus, we cannot rule out the possibility of achieving a higher sensitivity if DNA is extracted from the whole sample, including putative free-circulating DNA. On the other hand, since blood samples were obtained only once, low-grade intermittent parasitemia might have caused negative results. Another problem that should be addressed is that patients with chronic T gondii infection may have parasites appearing in the blood at intervals during asymptomatic phases of the disease. This may occur rarely, as shown by the negative results from the asymptomatic control group and by a high specificity of the PCR in this study. Dannemann et al. failed to isolate the parasite by animal inoculation in 111 follow-up blood samples from 33 human immunodeficiency virus-infected patients with IgG antitoxoplasma antibodies (11) . Finally, our results confirm that mouse inoculation is less sensitive than PCR for the detection of the parasite in both BAL fluid and blood.
In conclusion, examination of blood by PCR may be useful for the diagnosis of pulmonary and extracerebral toxoplasmosis, since most cases are associated with dissemination of the parasites in peripheral blood. Analysis by PCR of blood from patients with cerebral toxoplasmosis is valuable only (i) if the infection is associated with a disseminated spread of the parasite or severe encephalitis, which is not common since most cases result from local reactivation of latent brain cysts, and (ii) if the patients are not receiving any prophylactic or therapeutic treatment.
